Reduced hypothalamic-pituitary-adrenal axis activity in chronic multi-site musculoskeletal pain: partly masked by depressive and anxiety disorders

BMC Musculoskeletal Disorders

Joost Dekker³  Brenda WJH Penninx²  Johannes H Smit²  Rinie Geenen¹  Gary J Macfarlane⁴  Nicole Vogelzangs²  Ellen Generaal² 

[1] Department of Clinical and Health Psychology, Utrecht University, Utrecht, the Netherlands;Department of Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, PO Box 74077, 1070 BB Amsterdam, The Netherlands;Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, The Netherlands;Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, UK

关键词: Psychopathology;    Central sensitization;    Chronic pain;    Salivary cortisol;    Hypothalamic-pituitary-adrenal axis;   

Others  :  1125468
DOI  :  10.1186/1471-2474-15-227

 received in 2014-06-03, accepted in 2014-06-23,  发布年份 2014

【 摘 要 】

Background

Studies on hypothalamic-pituitary-adrenal axis (HPA-axis) function amongst patients with chronic pain show equivocal results and well-controlled cohort studies are rare in this field. The goal of our study was to examine whether HPA-axis dysfunction is associated with the presence and the severity of chronic multi-site musculoskeletal pain.

Methods

Data are from the Netherlands Study of Depression and Anxiety including 1125 subjects with and without lifetime depressive and anxiety disorders. The Chronic Pain Grade questionnaire was used to determine the presence and severity of chronic multi-site musculoskeletal pain. Subjects were categorized into a chronic multi-site musculoskeletal pain group (n = 471) and a control group (n = 654). Salivary cortisol samples were collected to assess HPA-axis function (awakening level, 1-h awakening response, evening level, diurnal slope and post-dexamethasone level).

Results

In comparison with the control group, subjects with chronic multi-site musculoskeletal pain showed significantly lower cortisol level at awakening, lower evening level and a blunted diurnal slope. Lower cortisol level at awakening and a blunted diurnal slope appeared to be restricted to those without depressive and/or anxiety disorders, who also showed a lower 1-h awakening response.

Conclusions

Our results suggest hypocortisolemia in chronic multi-site musculoskeletal pain. However, if chronic pain is accompanied by a depressive or anxiety disorder, typically related to hypercortisolemia, the association between cortisol levels and chronic multi-site musculoskeletal pain appears to be partly masked. Future studies should take psychopathology into account when examining HPA-axis function in chronic pain.

【 授权许可】

   
2014 Generaal et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Phillips K, Clauw DJ: Central pain mechanisms in the rheumatic diseases: Future directions. Arthritis Rheum 2013, 65:291-302.
• [2]Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM: Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998, 77:231-239.
• [3]Forseth KO, Forre O, Gran JT: A 5.5 year prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population: significance and natural history. Clin Rheumatol 1999, 18:114-121.
• [4]Carnes D, Parsons S, Ashby D, Breen A, Foster NE, Pincus T, Vogel S, Underwood M: Chronic musculoskeletal pain rarely presents in a single body site: results from a UK population study. Rheumatology (Oxford) 2007, 46:1168-1170.
• [5]Davies HT, Crombie IK, Macrae WA: Where does it hurt? Describing the body locations of chronic pain. Eur J Pain 1998, 2:69-80.
• [6]Kamaleri Y, Natvig B, Ihlebaek CM, Bruusgaard D: Localized or widespread musculoskeletal pain: does it matter? Pain 2008, 138:41-46.
• [7]Toomey TC, Mann JD, Abashian S, Thompson-Pope S: Relationship of pain drawing scores to ratings of pain description and function. Clin J Pain 1991, 7:269-274.
• [8]Kamaleri Y, Natvig B, Ihlebaek CM, Bruusgaard D: Does the number of musculoskeletal pain sites predict work disability? A 14-year prospective study. Eur J Pain 2009, 13:426-430.
• [9]Gerrits MM, Oppen PV, van Marwijk HW, Penninx BW, van der Horst HE: Pain and the onset of depressive and anxiety disorders. Pain 2013, 153:429-436.
• [10]Williams AC, Eccleston C, Morley S: Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012, 11:CD007407.
• [11]Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ: Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord 2004, 5:28. BioMed Central Full Text
• [12]Williams DA, Clauw DJ: Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009, 10:777-791.
• [13]Maletic V, Raison CL: Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci 2009, 14:5291-5338.
• [14]Tsigos C, Chrousos GP: Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002, 53:865-871.
• [15]McBeth J, Macfarlane GJ, Benjamin S, Silman AJ: Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum 2001, 44:940-946.
• [16]McCain GA, Tilbe KS: Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol Suppl 1989, 19:154-157.
• [17]Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL: Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994, 37:1583-1592.
• [18]Wingenfeld K, Wagner D, Schmidt I, Meinlschmidt G, Hellhammer DH, Heim C: The low-dose dexamethasone suppression test in fibromyalgia. J Psychosom Res 2007, 62:85-91.
• [19]Klerman EB, Goldenberg DL, Brown EN, Maliszewski AM, Adler GK: Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 2001, 86:1034-1039.
• [20]van Denderen JC, Boersma JW, Zeinstra P, Hollander AP, van Neerbos BR: Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity? Scand J Rheumatol 1992, 21:35-37.
• [21]Heim C, Ehlert U, Hellhammer DH: The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 2000, 25:1-35.
• [22]Macedo JA, Hesse J, Turner JD, Meyer J, Hellhammer DH, Muller CP: Glucocorticoid sensitivity in fibromyalgia patients: decreased expression of corticosteroid receptors and glucocorticoid-induced leucine zipper. Psychoneuroendocrinology 2008, 33:799-809.
• [23]Raison CL, Miller AH: When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003, 160:1554-1565.
• [24]McBeth J, Silman AJ, Gupta A, Chiu YH, Ray D, Morriss R, Dickens C, King Y, Macfarlane GJ: Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum 2007, 56:360-371.
• [25]McBeth J, Chiu YH, Silman AJ, Ray D, Morriss R, Dickens C, Gupta A, Macfarlane GJ: Hypothalamic-pituitary-adrenal stress axis function and the relationship with chronic widespread pain and its antecedents. Arthritis Res Ther 2005, 7:R992-R1000. BioMed Central Full Text
• [26]Turner-Cobb JM, Osborn M, Da SL, Keogh E, Jessop DS: Sex differences in hypothalamic-pituitary-adrenal axis function in patients with chronic pain syndrome. Stress 2010, 13:292-300.
• [27]Neeck G: Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol Suppl 2000, 113:8-12.
• [28]Neeck G, Riedel W: Hormonal pertubations in fibromyalgia syndrome. Ann N Y Acad Sci 1999, 876:325-338.
• [29]Goodin BR, Smith MT, Quinn NB, King CD, McGuire L: Poor sleep quality and exaggerated salivary cortisol reactivity to the cold pressor task predict greater acute pain severity in a non-clinical sample. Biol Psychol 2012, 91:36-41.
• [30]Geiss A, Varadi E, Steinbach K, Bauer HW, Anton F: Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent discectomy. Neurosci Lett 1997, 237:65-68.
• [31]Knorr U, Vinberg M, Kessing LV, Wetterslev J: Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 2010, 35:1275-1286.
• [32]Abelson JL, Khan S, Liberzon I, Young EA: HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety 2007, 24:66-76.
• [33]Vreeburg SA, Zitman FG, Van PJ, Derijk RH, Verhagen JC, Van DR, Hoogendijk WJ, Smit JH, Penninx BW: Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom Med 2010, 72:340-347.
• [34]Vreeburg SA, Hoogendijk WJ, Van PJ, Derijk RH, Verhagen JC, Van DR, Smit JH, Zitman FG, Penninx BW: Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 2009, 66:617-626.
• [35]Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P, Cuijpers P, de Jong PJ, van Marwijk HW, Assendelft WJ, der MK V, Verhaak P, Wensing M, De GR, Hoogendijk WJ, Ormel J, Van DR: The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008, 17:121-140.
• [36]Von Korff KM, Ormel J, Keefe FJ, Dworkin SF: Grading the severity of chronic pain. Pain 1992, 50:133-149.
• [37]Elliott AM, Smith BH, Smith WC, Chambers WA: Changes in chronic pain severity over time: the Chronic Pain Grade as a valid measure. Pain 2000, 88:303-308.
• [38]Smith BH, Penny KI, Purves AM, Munro C, Wilson B, Grimshaw J, Chambers WA, Smith WC: The Chronic Pain Grade questionnaire: validation and reliability in postal research. Pain 1997, 71:141-147.
• [39]Von Korff KM: Epidemiologic and Survey Methods: Chronic Pain Assessment. In Handbook of Pain Assessment. 2nd edition. Edited by Turk DC, Melzack R. New York: Guilford Press; 2001:603-618.
• [40]Vreeburg SA, Kruijtzer BP, Van PJ, Van DR, DeRijk RH, Hoogendijk WJ, Smit JH, Zitman FG, Penninx BW: Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. Psychoneuroendocrinology 2009, 34:1109-1120.
• [41]Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH: Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003, 28:916-931.
• [42]Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. Geneva, Switzerland: World Health Organization; 2001.
• [43]Ainsworth BE, Bassett DR Jr, Strath SJ, Swartz AM, O'Brien WL, Thompson RW, Jones DA, Macera CA, Kimsey CD: Comparison of three methods for measuring the time spent in physical activity. Med Sci Sports Exerc 2000, 32:S457-S464.
• [44]Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA: The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988, 45:1069-1077.
• [45]World Health Organization Collaborating Center for Drugs Statistics Methodology: Anatomical Therapeutic Chemical (ATC) Classification. Geneva, Switzerland; 2007. [ http://www.whocc.no/atc_ddd_index/ webcite]. Accessed January 2013
• [46]Manthey L, Leeds C, Giltay EJ, Van VT, Vreeburg SA, Penninx BW, Zitman FG: Antidepressant use and salivary cortisol in depressive and anxiety disorders. Eur Neuropsychopharmacol 2011, 21:691-699.
• [47]Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA, Wells CD: Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010, 85:S3-S14.
• [48]Riva R, Mork PJ, Westgaard RH, Lundberg U: Comparison of the cortisol awakening response in women with shoulder and neck pain and women with fibromyalgia. Psychoneuroendocrinology 2012, 37:299-306.
• [49]Griep EN, Boersma JW, de Kloet ER: Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993, 20:469-474.
• [50]Griep EN, Boersma JW, Lentjes EG, Prins AP, van der Korst JK, de Kloet ER: Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998, 25:1374-1381.
• [51]Carroll BJ, Cassidy F, Naftolowitz D, Tatham NE, Wilson WH, Iranmanesh A, Liu PY, Veldhuis JD: Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand Suppl 2007, 433:90-103.
• [52]Rief W, Hennings A, Riemer S, Euteneuer F: Psychobiological differences between depression and somatization. J Psychosom Res 2010, 68:495-502.
• [53]Geenen R, Jacobs JW, Bijlsma JW: Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 2002, 28:389-404.
• [54]Davies KA, Macfarlane GJ, Nicholl BI, Dickens C, Morriss R, Ray D, McBeth J: Restorative sleep predicts the resolution of chronic widespread pain: results from the EPIFUND study. Rheumatology (Oxford) 2008, 47:1809-1813.
• [55]Hansen AM, Garde AH, Persson R: Sources of biological and methodological variation in salivary cortisol and their impact on measurement among healthy adults: a review. Scand J Clin Lab Invest 2008, 68:448-458.
• [56]Tak LM, Cleare AJ, Ormel J, Manoharan A, Kok IC, Wessely S, Rosmalen JG: Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol Psychol 2011, 87:183-194.
• [57]Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.